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Abstract 
Background: To compare ethinyl estradiol-
cyproterone acetate and metformin for polycystic 
ovarian syndrome in terms of mean hirsutism score 
and waist hip ratio (WHR). 
Methods: A total of 120 patients (60 patients in 
each group) were included in the study. Group-A 
received metformin 500mg and group-B was given 
ethinyl estradiol 35 mg as treatment of polycystic 
ovary disease (PCOD), mean hirsuitism and waist to 
hip ratio was measured at 6months. Hirsuitism was 
measured according to Ferriman  Gallway score. 
Circumferences were  measured with an 
anthropometric tape over light clothing. Waist girth 
was measured at the minimum circumference 
between the iliac crest and the rib cage and hip girth 
at the maximum width and their ratio was calculated 
as baseline and after 6 months of treatment. 
Results: Mean age was 25.87±6.46 and 25.60±6.74, 
respectively. Mean waist hip ratio at presentation 
and after 6 months was proportionate in the two 
groups. Mean hirsutism score at baseline was 
tantamount in both groups but at 6 months 
significant reduction (p<0.001) was seen in Group-B 
(Ethinyl estradiol Cyproterone acetate) when 
compared with Group-A (Metformin). Mean BMI 
was 29.77±3.77 and 29.82±3.02 in group-A and B, 
respectively. Stratification with regard to age and 
BMI in terms of waist to hip ratio and mean 
hirsutism score was also carried out. 
Conclusion: Ethinyl estradiol cyproterone acetate 
(EE-CA) proved beneficial for reduction of mean 
hirsutism score in patients with PCOS, but it has no 
role in reducing WHR when compared with 
metformin. 
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Introduction 
Polycystic ovary syndrome (PCOS) is an important 
cause of hyperandrogenemia in women with familial 
predisposition. The rudimentary quandary is in the 
hypothalamic pituitary axis leading to incremented 
LH/FSH ratio1. The cumulation of anovulation and 
hyperandrogenism denotes the classic form of PCOS 
which exhibits the adverse metabolic phenotype of the 
syndrome. Clinical and biochemical features of these 
patients may vary well-according to race, ethnicity and 
the diagnostic criteria used. 2 Hyper-androgenism  
may result in acne and hirsutism. Hirsutism afflicts 5-
15% of females and is a paramount denouement of 
background hyper-androgenemia. The manifestations 
of polycystic ovary syndrome depends largely on 
obesity, which exacerbates the reproductive and 
metabolic aberrations in women tormented by PCOs. 
Further studies conclude that obesity might promote 
the phenotypic expression of PCOS in a population at 
risk of this disease.1,2 
Well known risk determinants for cardiovascular 
disease are abnormal glucose tolerance and diabetes 
myelitis. A proportion ( 18-20%) of overweight women 
suffering from polycystic ovary syndrome 
demonstrate to have an impaired glucose tolerance3. 
Most of the women suffering from type 2 diabetes 
under the age of 45 years have polycystic ovaries. 
Insulin resistance coalesced with abdominal obesity is 
considered to be associated with higher pervasiveness 
of T2DM in PCOS. There is a concomitant incremented 
risk of gestational diabetes4 
As metabolic syndrome and T2DM is more common in 
our part of the world it would be interesting to see 
how individuals fare  in such a comparative trial in 
our part of the world. 
 
Patients and Methods 
 This randomized controlled trial  was conducted  in  
Department of  Gynaecology/Obstetric ,  MH/CMH 
Rawalpindi. It was carried out over a period of six 
months from  January 2014 to  June 2014 (follow up 
completed on 31-10-2014). A total of 120 patients were 
taken. All Women diagnosed to be having PCOS 
between 15-40 years were included excluding 
pregnant women, hypertensive or diabetics. The 
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patients were included on the basis of non-probability 
consecutive sampling. Baseline waist to hip ratio and 
hirsutism score (according to Ferrimen Gallway score) 
of women having polycystic ovaries is noted. Waist 
and hip circumferences were quantified with an 
anthropometric tape by AFNS officer. BMI measured 
and waist girth was quantified at the minimum 
circumference between the iliac crest and the rib cage 
and hip girth at the maximum width. Patients were 
randomized by lottery method to the metformin or 
oral contraceptive pill group [ethinylestradiol (35 
mcg), CA (2 mg) 21 days/month followed by a 7-day 
gap]. The metformin was given in dose of 500mg 
thrice a day. After 6 months of treatment waist to hip 
ratio and hirsutism score (according to Ferrimen 
Gallway score) was noted. Independent sample t-test 
was applied for comparison of WHR and Hirsutism 
score in two groups. A p-value < 0.05 was considered 
statistically significant. Stratification was done to 
control effect modifiers like age and BMI. 
 
Results 
A total of 120 patients (60 patients in each group) were 
taken in present study during the study period of six 
months.Group-A received metformin 500mg while 
Group-B was administered ethinyl estradiol 35 mg.
 In group-A, 42 patients (70.0%) and in group-
B, 44 patients (73.3%) were between 15-30 years of age. 
Eighteen patients (30.0%) from group-A and 16 
patients (26.7%) from group-B were 31-40 years old. 
Mean age was 25.87±6.46 and 25.60±6.74, 
respectively.Mean waist hip ratio at baseline and after 
6 months was comparable in both groups (Table-1).. 
 
Table 1:Comparison of mean waist hip ratio 
Group At booking At 6 months 
Group-A(Metformin) 0.821±0.049 0.812±0.043 
Group-B(Ethinyl 
estradiol Cyproterone 
acetate) 
0.836±0.056 0.800±0.055 
p value p=0.131 p=0.205 
Table 2:Comparison of mean hirsutism score 
Group At booking At 6 months 
Group-A(Metformin) 20.38±3.15 18.78±3.29 
Group-B(Ethinyl 
estradiol Cyproterone 
acetate ) 
19.62±2.95 15.08±3.06 
p- value P=0.172 P<0.001 
 
Mean hirsutism score at baseline was comparable in 
both groups but at 6 months significant reduction 
(p<0.001) was seen in Group-B (Ethinyl estradiol 
Cyproterone acetate) when compared with Group-A 
(Metformin) (Table-2). Mean BMI was 29.77±3.77 and 
29.82±3.02 in group-A and B, respectively(Table-
3).Stratification with regard to age and BMI in terms of 
waist to hip ratio and mean hirsutism score 
 
Table 3:Comparison of BMI 
BMI 
Group-A 
(Metformin) 
 
Group-B 
Ethinyl estradiol 
Cyproterone acetate 
 
< 25 07 (11.7%) 4 (6.7%) 
> 25 53 (88.3%) 56 (93.3%) 
Total 60 (100.0%) 60 (100.0%) 
Mean±SD 29.77±3.77 29.82±3.02 
 
Discussion 
Polycystic ovary syndrome (PCOS) accounts for a high 
 prevalent endocrine abnormality inflicting 
reproductive age females, being annotated by 
anovulation, hyperandrogenemia, obesity and 
resistance to insulin.1,2 The general presentation of 
PCOS are menstrual irregularities encompassing 
oligo/amenorrhea or dysfunctional uterine bleeding; 
hyperandrogenism features including hirsutism, acne, 
oily skin and androgenic alopecia; along with 
infertility and obesity. Impaired glucose tolerance 
(IGT), type-2 diabetes mellitus, metabolic syndrome5, 
non-alcoholic steatohepatitis, sleep apnea syndrome, 
endometrial, ovarian or breast malignancy and 
increased cardiovascular risk are other clinical 
conditions related with PCOs.3-5 
A lengthy evolution process and environmental 
adaptations lead to variation in human body 
composition.5 Conspicuously, the morphological body 
parameters, physiological and biochemical indices are 
intricate and hence they complicate the interdependent 
system.6 According to recent literature, overweight or 
obese women account for more than 50%. 7The 
reproductive and metabolic functions of a female is 
affected adversely even more if PCOS induced waist 
circumference and waist-to-hip ratio increases.8 The 
subcutaneous and visceral fat topography has been 
proved to be the strongest sexual dimorphism sign 
which shows that the women suffering from PCOS 
have higher fatty deposits in abdomen, waist and 
upper arms compared to other women6,9. 
Decrease in weight and decrement in waist–hip ratio 
has been proclaimed while utilizing metformin.10 
Weight loss and metformin cause virtually similar 
effects in women suffering from PCOS thus some 
authors consider metformin-induced weight loss to be 
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the actual indirect sequel of amelioration compared to 
the direct effect of metformin.11 Alleviation of body 
mass index (BMI) and waist–hip ratio can indubitably 
accord to amelioration.12 
Hirsutism is excess hair growth in characteristic male 
distribution areas, like chin, upper lip, breasts, back, 
and abdomen.2,3 Hirsutism is classically, thought of as 
a marker of incremented levels of androgens in 
women either from adrenals or ovarian disease13. 
Ovarian types of hyperandrogenism being the 
polycystic ovarian syndrome (PCOS) and ovarian 
tumors ,Hyperandrogenic insulin-resistant acanthosis 
nigricans syndrome (HAIR-AN)15 being less common 
cause. 14,15 
Hirsutism has led to psychological constraints causing 
women to have anxiety and depression.16 One study 
concluded that the average time spent per week in 
dealing with facial hair by women suffering from 
hirsuitism due to PCOS was 104 minutes with majority 
checking facial hair frequently and upto 75% showed 
clinically significant concern and anxiety.17Hirsutism is 
a universal medical complaint of females in 
reproductive age18,with a prevalence of 3 to 15% in 
Blacks and Whites19 and 1-3% in Asians.18-20 Recent 
epidemiological surveys however have restricted 
hirsuitism to adolescence and youth with a prevalence 
ranging from 8 to 13%.20,21 Polycystic ovary 
syndrome (PCOS) represents the commonest cause of 
hirsuitism.22 A recent report by the Androgen Excess-
PCOS Society reviewed 18 studies published from 
1983 to 2007, including 6281 females suffering from 
PCOS, and concluded that 74.7% of females had 
hirsutism on initial diagnosis with a severer form and 
abdominal phenotype obesity.23,24 Interestingly, albeit 
hirsutism does not plenarily soothsay ovulatory 
dysfunction, few authors concluded that it might 
prognosticate the metabolic aftermath or conception 
failure despite infertility treatment in patients of 
PCOS.21,23 
Combined oral contraceptives contain a progestin and 
a synthetic estrogen i.e  ethinyl estradiol.11,12 Other 
progestins including Drospirenone and cyproterone 
acetate (CPA), show antiandrogenic activity but are 
not structurally testosterones. CPA inhibits androgen 
receptors and hence 5--reductase activity, thus 
alleviating androgen levels in serum.21 Drospirenone 
however lowers the blood pressure due to its 
additional anti-mineralocorticoid property.22 
Conclusively, drospirenone in CPA and COCs 
suppresses the ovarian androgen production by 
blocking LH secretion, decreases serum free 
testosterone levels by augmenting SHBG synthesis in 
the liver and blocks androgen receptors.24 COCs are 
being used in the management of PCOS for 
approximately 30 years, with multiple studies 
elucidating the role of COCs on carbohydrate 
metabolism, lipid profile and cardiovascular risk 
parameters.24,25 
Metformin decrements production of ovarian 
androgen by mitigating the serum insulin levels and 
insulin resistance, leading to decreased serum 
testosterone level, eventually the hirsutism score and 
menstrual dysfunction improves and hence reversal of 
infertility. 13,21 
In present study, reduction in waist hip ratio was 
comparable at 6 months (p=0.205) when Metformin 
and Ethinyl estradiol Cyproterone acetate group 
compared. Comparison of hirsutism score between 
Metformin and Ethinyl estradiol group reveals 
significant reduction in Ethinyl estradiol Cyproterone 
acetate group (18.78±3.29 vs 15.08±3.06) p<0.001. 
Results of present study are comparable with the 
findings of El Maghraby et al.25 
 
Conclusion 
1.Ethinyl estradiol cyproterone acetate (EE-CA) 
appears to be an adequate therapeutic option for 
reduction of mean hirsutism score in patients with 
PCOS, but it has no role in reducing WHR when 
compared with metformin.  
2.Metformin alleviates hyperandrogenism, 
hyperinsulinemia, and menstrual cyclicity, due to its 
affirmative effect on insulin clearance and abdominal 
obesity.  
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